The European Commission (EC) has extended the approval for Rybrevant (amivantamab), in combination with Lazcluze (lazertinib), to the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC). It is specifically approved for use in patients with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R substitution mutations. “For […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!